All In Biotech

NDA 208418 · Fresenius Kabi USA

Calcium Gluconate

Calcium Gluconate · Intravenous

Last checked: Nov 20, 2026Latest source record: Oct 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 15, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

404

89 Phase 3, 25 recruiting

FAERS reports

12,181

10,040 serious, 2,619 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Calcium Gluconate Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. ( 1 ) Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established. ( 1 ) Limitations of Use The safety of Calcium Gluconate Injection for long term use has not been established.

Mechanism: Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are normal constituents of body fluids.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • CALCIUM GLUCONATE · CALCIUM GLUCONATE 10GM/100ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • CALCIUM GLUCONATE · CALCIUM GLUCONATE 1GM/10ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • CALCIUM GLUCONATE IN SODIUM CHLORIDE · CALCIUM GLUCONATE 1GM/50ML (20MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued · TE AP
  • CALCIUM GLUCONATE · CALCIUM GLUCONATE 5GM/50ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • CALCIUM GLUCONATE IN SODIUM CHLORIDE · CALCIUM GLUCONATE 2GM/100ML (20MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Gluconate" as an intervention, any sponsor and status, largest first.

All 404 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,241
  • pain1,748
  • fatigue1,724
  • off label use1,670
  • rheumatoid arthritis1,435
  • nausea1,420
  • alopecia1,369
  • vomiting1,331
  • pemphigus1,301
  • arthropathy1,290
  • abdominal discomfort1,284
  • psoriatic arthropathy1,283

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004223
20052,287
20061,041
200789
2008283
2009112
2010104
2011124
2012178
2013170
2014163
2015203
2016258
2017335
2018393
2019543
2020688
2021702
2022936
2023900
2024874
20251,059
2026516

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Calcium Gluconate (Calcium Gluconate)

2024 spending

$62K

Beneficiaries

64

681 claims

Per beneficiary

$964

$0.47 per unit

View as table
YearSpending
2020$41,454
2021$84,407
2022$86,574
2023$67,336
2024$61,699

Part B: Calcium Gluconate* (Calcium Gluconate*) · HCPCS J0612

2024 spending

$201K

Beneficiaries

11,987

25,471 claims

Per beneficiary

$17

2024 ASP limit $0.04 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$18,423
2024$201,493

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,015 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Calcium Gluconate In Sodium Chloride

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.